Accelerate to discover

Back to filter

Related topics

Cytek Biosciences hits flow cytometry milestone: 40 color analysis from a single sample

Cytek Biosciences

Oct 17, 2019

Cytek Aurora turning aspirations into realizations: 40 Colors, One Tube. Until recently, developing fluorescence-based...

Vascular imaging using a contrast-enhanced microCT approach

Bruker Biospin

Oct 14, 2019

Are you interesting in MicroangioCT? Do you heard about Vascular imaging using a contrast-enhanced microCT approach?...

Change the way you process cells with Curiox Laminar Wash systems

Curiox

Oct 8, 2019

Laminar Wash technology is for scientists who believe that quantitative flow cytometry is critical to cell therapy,...

Webinar recording - Highly sensitive structural variant detection for medical genetics

BioNano Genomics

Oct 4, 2019

Follow the webinar outlining how a team at Radboud University Medical Center is assessing ultra-long read optical...

Oct 21, 2019

Cytek users evening forum

Cytek Biosciences

Sep 30, 2019

Enjoy an evening to meet with Cytek technical application specialists and technical sales representatives and share...

VisualSonics AutoLV

VisualSonics FujiFilm

Sep 27, 2019

VisualSonics AutoLV allow functional and anatomical analysis of the left ventricle in one click using the power of...

Unlimited capabilities of IncuCyte system: discover the latest Cell Cycle assays

Sartorius

Sep 23, 2019

The IncuCyte Cell Cycle Assay combines easy-to-learn automated image acquisition and integrated analysis of 96- or...

Oct 21, 2019

The fastest qPCR thermal cycler in the world

BJS Biotechnologies

Sep 19, 2019

With a thermal ramp rate of up to 10°C per second, the xxpress NGx is the fastest, real-time thermal cycler in the...

Show all topics (10)

Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer

Jun 1, 2018

The 10‐year survival rate of cancer patients has greatly increased over the last 20 years. However, the survival rate of patients with major malignant tumors, such as lung and pancreatic cancers, still shows negligible improvement.The conventional chemotherapeutic strategy for treating lung cancer remains unsatisfactory in this respect. Specifically, the 5‐year survival rates of both non‐small‐cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients exhibited merely 4–5% improvements in the past decade for cancer in stages I–III.2 The main difficulty in treating lung cancer is the lack of targeted chemotherapeutic agents specific to the lung tumor tissues and, thus, non‐specific targeting generally leads to unwanted side effects induced by excessive doses of chemotherapeutic agents.

Several strategies have been introduced to resolve the aforementioned issues, such as cancer antigen‐targeted monoclonal antibody (mAb) therapy,4 nanodrug delivery,5 and cell‐mediated therapy (i.e., T‐cell‐based therapy for NSCLC6). However, many clinical trials have shown that intravenously administered mAb, particularly epidermal growth factor receptor‐targeting mAbs, induced dermatological toxicities (e.g., acneiform eruption, xerosis, telangiectasia, hyperpigmentation, fissures, and hair/nail changes) in over 50% of patients after treatment.

Read more!

Scientific paper
Application

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Yokogawa

Yokogawa is a leading provider of confocal quantitative live cell imaging platforms. Combining superior technology with engineering services, project management, and maintenance, Yokogawa delivers field proven operational efficiency, safety, quality, and reliability. 

Related products

Confocal quantitative image cytometer CQ1 offers a new approach to image quantification

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey